
Ask a doctor about a prescription for MEMANTINE PENSA 20 mg FILM-COATED TABLETS
Leaflet:information for the patient
Memantina Pensa 20 mg film-coated tablets EFG
Memantine hydrochloride
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the leaflet
How Memantina Pensa works
Memantina Pensa belongs to a group of medications called anti-dementia medications. Memory loss in Alzheimer's disease is due to an alteration in brain signals. The brain contains so-called N-methyl-D-aspartate (NMDA) receptors that participate in the transmission of important nerve signals in learning and memory. Memantina Pensa belongs to the group of medications called NMDA receptor antagonists. Memantina Pensa acts on these receptors, improving the transmission of nerve signals and memory.
What Memantina Pensa is used for:
Memantina Pensa is used in the treatment of patients with moderate to severe Alzheimer's disease.
Do not take Memantina Pensa:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Memantina Pensa:
In these situations, treatment should be carefully monitored, and your doctor should regularly reassess the clinical benefit of Memantina Pensa.
If you have kidney problems, your doctor should closely monitor your kidney function and, if necessary, adjust the dose of memantine.
The use of memantine with other medications such as amantadine (for the treatment of Parkinson's disease), ketamine (a medication generally used to produce anesthesia), dextromethorphan (a medication for the treatment of cough), and other NMDA antagonists should be avoided.
Children and adolescents
The use of Memantina Pensa is not recommended in children and adolescents under 18 years of age.
Taking Memantina Pensa withother medications
Tell your doctor or pharmacist if you are using, have recently used, or may need to take any other medication.
In particular, the administration of Memantina Pensa may produce changes in the effects of the following medications, so your doctor may need to adjust the doses:
If you are hospitalized, inform your doctor that you are taking Memantina Pensa.
Taking Memantina Pensa with food and drinks
You should inform your doctor if you have recently changed or plan to change your diet substantially (e.g., from a normal diet to a strict vegetarian diet) or if you have renal tubular acidosis (RTA, excess of acid-producing substances in the blood due to kidney dysfunction) or severe urinary tract infections (urinary tract), as your doctor may need to adjust the dose of the medication.
Pregnancy andbreastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
The use of memantine is not recommended in pregnant women.
Women taking Memantina Pensa should stop breastfeeding.
Driving and using machines
Your doctor will inform you if your illness allows you to drive and use machines safely.
Additionally, Memantina Pensa may alter your reaction ability, so driving or operating machines may be inappropriate.
Follow the administration instructions of this medication exactly as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Posology
The recommended dose of Memantina Pensa in adult patients and elderly patients is 20 mg administered once daily. To reduce the risk of side effects, this dose is gradually achieved following the daily scheme. To adjust the dose, there are tablets with different doses.
Week 1 | half a 10 mg tablet |
Week 2 | one 10 mg tablet |
Week 3 | one and a half 10 mg tablets |
Week 4 and subsequent weeks | two 10 mg tablets once daily |
At the start of treatment, you will begin taking half a 10 mg tablet once daily. This dose will be increased weekly by 5 mg until the recommended maintenance dose is reached (20 mg). The recommended maintenance dose is 20 mg once daily, which is reached at the beginning of the fourth week.
Posology for patients with renal impairment
If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should periodically monitor your kidney function.
Administration
Memantina Pensa should be administered orally once daily. To get the most out of your medication, you should take it every day and at the same time. The tablets should be swallowed with a little water. The tablets can be taken with or without food.
Duration of treatment
Continue taking Memantina Pensa as long as it is beneficial for you. Your doctor should periodically evaluate the effects of your treatment.
If you take more Memantina Pensa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
Generally, taking an excessive amount of Memantina Pensa should not cause you any harm. You may experience an increase in the symptoms described in section 4.
If you forget to take Memantina Pensa
If you realize you have forgotten to take your dose of Memantina Pensa, wait and take the next dose at the usual time. Do not take a double dose to make up for the missed dose.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Generally, side effects are classified as mild to moderate.
Frequent (may affect 1 to 10 in 100 patients):
Uncommon (may affect 1 to 10 in 1,000 patients):
Very rare (may affect less than 1 in 10,000 people):
Frequency not known (frequency cannot be estimated from available data):
Alzheimer's disease has been associated with depression, suicidal ideation, and suicide. These events have been reported in patients treated with memantine.
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are possible side effects not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the carton and blister. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medication in the pharmacy's SIGRE collection point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Memantina Pensa
Appearance of the product and package contents
Memantina Pensa 20 mg is presented in the form of film-coated tablets, pale red in color, oval, and scored on one side. It is presented in PVC-PVDC/Aluminum blisters containing 28 and 56 tablets.
The tablets can be divided into equal doses.
Not all pack sizes may be marketed.
Marketing authorization holder
Towa Pharmaceutical, S.A.
C/ de Sant Martí, 75-97
08107 Martorelles (Barcelona)
Spain
Manufacturer
NOUCOR HEALTH, S.A.
Av. Camí Reial, 51-57
08184 – Palau-solità i Plegamans, Barcelona
Spain
This medication is authorized in the Member States of the European Economic Area under the following names:
PT: Memantina Pensa, 20 mg, film-coated tablets.
ES: Memantina Pensa 20 mg film-coated tablets EFG
Date of the last revision of this leaflet:January 2018
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MEMANTINE PENSA 20 mg FILM-COATED TABLETS – subject to medical assessment and local rules.